RxDoctor Payments Data

Andrew Morris, DO

Urology · Overland Park, KSNPI 1245492602

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,039 of the $5,512 with a category attached, or 73.3%. 41 manufacturers reported payments, led by Neotract Inc. at 26.5% of the total. Reporting peaked in 2019 at $1,773 and has fallen 81.3% since, to $331 in 2025.

$5,512in general payments, 2019–2025

Across 234 payments — averaging $23.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$1K
  • AbbVie$604
  • Endo Pharmaceuticals Inc.$513
  • Antares Pharma, Inc.$300
  • Axonics, Inc.$234
  • Astellas Pharma US Inc$215
  • plus $2K from 35 others

What the payments were for

  • Travel & lodging$1,30424%
  • Food & beverage$4,03973%
  • Education$1693%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,512 in reported general payments places this provider in the 70th percentile of 111 urology providers in Kansas.

See all urology providers in Kansas

Medicare billing

Part B allowed, 2024
$247,113
Medicare patients
550
Services billed
4,896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron138$92,844
GemtesaVibegron18$14,231
Finasteride639$6,494
Methenamine Hippurate159$6,105
Trospium Chloride95$5,221
Tamsulosin Hcl379$5,219
Alfuzosin Hcl ErAlfuzosin Hcl273$4,123
Solifenacin Succinate102$2,962
Dutasteride100$2,705
Tolterodine Tartrate ErTolterodine Tartrate29$2,043
Trospium Chloride ErTrospium Chloride12$2,029
Trimethoprim53$2,010
Oxybutynin Chloride ErOxybutynin Chloride114$1,865
Potassium Citrate ErPotassium Citrate21$1,782
Estradiol29$1,775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$215$92,844138 claims
Sumitomo Pharma America, Inc.Gemtesa$109$14,23118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 111 urology providers in Kansas.

Other urology in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →